Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBLI Cleveland BioLabs (CBLI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Cleveland BioLabs Stock (NASDAQ:CBLI) 30 days 90 days 365 days Advanced Chart Get Cleveland BioLabs alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.20▼$4.3452-Week Range N/AVolume304 shsAverage Volume271,922 shsMarket Capitalization$5,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.Read More… Receive CBLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cleveland BioLabs and its competitors with MarketBeat's FREE daily newsletter. Email Address CBLI Stock News HeadlinesEagles' Tyrie Cleveland, Moro Ojomo carted off field after suffering neck injuriesSeptember 2, 2023 | usatoday.comCleveland Construction NewsJuly 28, 2023 | bizjournals.comThe FED is losing the war on inflation It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…February 23, 2025 | WealthPress (Ad)Best Hospitals in Cleveland, OHJune 28, 2023 | health.usnews.comCleveland EMS worker who went missing for 6 days remains hospitalized after found safeMay 22, 2023 | abcnews.go.comCleveland Clinic Rehabilitation HospitalMay 17, 2023 | health.usnews.comGetting Around ClevelandApril 19, 2023 | travel.usnews.comCleveland BioLabs Stock Gaps Down On Today's Open (CBLI)March 31, 2023 | thestreet.comSee More Headlines CBLI Stock Analysis - Frequently Asked Questions How were Cleveland BioLabs' earnings last quarter? Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced its quarterly earnings data on Friday, May, 15th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company earned $0.16 million during the quarter. What other stocks do shareholders of Cleveland BioLabs own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cleveland BioLabs investors own include iBio (IBIO), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Novavax (NVAX) and BioCryst Pharmaceuticals (BCRX). Company Calendar Last Earnings5/15/2020Today2/23/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CBLI CUSIPN/A CIK1318641 Webwww.cbiolabs.com Phone(888) 613-8802FaxN/AEmployees4Year Founded2003Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.84% Return on Assets-31.29% Debt Debt-to-Equity RatioN/A Current Ratio45.93 Quick Ratio45.93 Sales & Book Value Annual Sales$260,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / BookN/AMiscellaneous Outstanding Shares15,479,000Free FloatN/AMarket Cap$5,000.00 OptionableNot Optionable Beta0.70 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CBLI) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cleveland BioLabs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
